Patent · US Active

Abiraterone prodrugs

US12138273B2 · kind B2 · utility

0Cited by

16References

34Claims

0Family size

Assignee

PROPELLA THERAPEUTICS, INC. · US

Inventors

Matthew J. SHARP · Apex, US
William R. Moore · Pittsboro, US

Key dates

Filing date	Jan 19, 2023
Grant date	Nov 12, 2024
Priority date	—
Expiry date	May 5, 2043

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P35/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Sustained-release abiraterone prodrug formulations, methods, and kits for parenteral administration to a subject having a sex hormone-dependent benign or malignant disorder such as prostate cancer, a syndrome due to androgen excess, and/or a syndrome due to glucocorticoid excess such as hypercortisolemia.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.